Amlodipine
- Generic Name
- Amlodipine
- Brand Names
- Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
- Drug Type
- Small Molecule
- Chemical Formula
- C20H25ClN2O5
- CAS Number
- 88150-42-9
- Unique Ingredient Identifier
- 1J444QC288
- Background
Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnorma...
- Indication
Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :
• Hypertension
• Coronary artery disease
• Chronic stable angina
• Vasospastic angina (Prinzmetal’s or Variant angina)
...
- Associated Conditions
- Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina
- Associated Therapies
- -
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 698
- Registration Number
- NCT00413049
- Locations
- 🇨🇳
Institute of Hypertension, Ruijin Hospital, Shanghai, China
🇨🇳Zhongshan hospital affiliated Fudan University, Shanghai, China
🇨🇳The sixth people's hospital of Shanghai, Shanghai, China
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
- Conditions
- Interventions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2021-02-11
- Target Recruit Count
- 245
- Registration Number
- NCT00412113
- Locations
- 🇺🇸
Pfizer Investigational Site, Chesapeake, Virginia, United States
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
- Conditions
- First Posted Date
- 2006-12-11
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1259
- Registration Number
- NCT00409643
- Locations
- 🇩🇪
Sites in Germany, Germany, Germany
🇺🇸Novartis Pharmaceuticals, East Hanover, New Jersey, United States
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 556
- Registration Number
- NCT00402103
- Locations
- 🇩🇪
Investigative Center, Investigative Center, Germany
🇧🇪Investigator Site, Investigative Site, Belgium
🇨🇭Investigative Site, Investigative Site, Switzerland
Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia
- Conditions
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2006-10-12
- Lead Sponsor
- Luzerner Kantonsspital
- Registration Number
- NCT00382421
- Locations
- 🇨🇭
Department of Cardiology, Hospital Lucerne, Lucerne, Switzerland
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 901
- Registration Number
- NCT00368277
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide
- Conditions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 198
- Registration Number
- NCT00360178
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
- Conditions
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 79
- Registration Number
- NCT00351130
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
The Effect of Amlodipine and Lisinopril on Retinal Autoregulation in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2009-06-23
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 25
- Registration Number
- NCT00337298
- Locations
- 🇩🇰
Aarhus university hospital, Aarhus, Denmark
Caduet in an Untreated Subject Population
- Conditions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2021-01-27
- Target Recruit Count
- 220
- Registration Number
- NCT00332761
- Locations
- 🇺🇸
Pfizer Investigational Site, Norfolk, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.